Layer-by-layer fabrication of living tissues using cells, biomaterials, and growth factors - building the future of regenerative medicine and organ transplantation
3D bioprinting is a revolutionary additive manufacturing technology that creates three-dimensional tissue constructs by depositing living cells, biomaterials, and bioactive molecules in precise spatial patterns. Unlike traditional 3D printing that uses plastics or metals, bioprinting works with "bioinks" - cell-laden hydrogels that support cell viability during and after the printing process.
The technology enables researchers to fabricate complex tissue architectures that mimic native organ structures, including multiple cell types arranged in physiologically relevant configurations. Bioprinted tissues can mature in bioreactors to develop functional characteristics before transplantation or use in drug testing.
In 2023, researchers at Tel Aviv University bioprinted the first miniature heart with blood vessels using patient cells, demonstrating the potential for personalized, rejection-free organ transplants within the next two decades.[4]
Four primary technologies dominate the bioprinting landscape, each with distinct advantages for specific applications:
Continuous deposition of bioink through a nozzle using pneumatic or mechanical pressure. Most common method for structural tissues.
100-500 um resolutionThermal or piezoelectric actuation deposits precise droplets. Excellent for patterning multiple cell types with high precision.
20-100 um resolutionLaser pulses transfer cells from a donor ribbon. Highest resolution and cell viability but lower throughput.
10-50 um resolutionUV light crosslinks photosensitive bioinks layer by layer. Creates complex geometries with smooth surfaces.
25-100 um resolutionBioinks must balance multiple requirements: printability (viscosity and crosslinking), biocompatibility (cell survival), and functionality (supporting tissue maturation). Key materials include:
Alginate, Collagen, Fibrin, Gelatin, Hyaluronic Acid - Derived from biological sources, these materials closely mimic native extracellular matrix and support excellent cell behavior.
PEG, Pluronic, PCL - Offer tunable mechanical properties and degradation rates. Often combined with natural materials for optimal performance.
Organ-specific matrices retain native biochemical cues and architecture. Derived from donor tissues, providing tissue-specific environments for printed cells.
Photo-crosslinkable gelatin derivative combining natural cell adhesion sites with tunable mechanical properties. Widely used across bioprinting applications.
Bioprinted tissue models replicate human disease states for studying pathophysiology and screening therapeutics with human-relevant results.
In Use3D liver, kidney, and cardiac models detect drug toxicity earlier than 2D cultures or animal models, reducing late-stage clinical failures.
In UseBioprinted skin constructs for burn victims and wound healing. Several companies have products in advanced clinical development.
Clinical TrialsPrinted cartilage implants for joints and ears. Less demanding than vascularized tissues due to cartilage's avascular nature.
Clinical TrialsBioprinted bone grafts with osteogenic cells for fracture repair and reconstructive surgery.
Clinical TrialsFully functional organs (kidney, liver, heart) for transplantation. The ultimate goal requiring vascularization solutions.
Research PhaseWhile fully functional organs remain years away, significant milestones demonstrate rapid progress toward this goal:
Vascularization remains the single greatest obstacle to printing transplantable organs. Cells cannot survive more than 100-200 micrometers from a blood supply.[5] Without functional vessels, the core of any printed tissue larger than a few millimeters dies within hours.
Current approaches to solving this challenge include:
Companies like Prellis Biologics claim breakthroughs in printing microvasculature at the capillary scale, potentially unlocking larger, more complex tissue constructs.
Pioneered exVive liver tissue for drug testing; advancing therapeutic liver tissue programs
Leading bioprinter manufacturer; comprehensive bioink portfolio and life science tools
Microfluidic bioprinting platform; partnership with Novo Nordisk for islet replacement
Healthcare 3D printing including bioprinting; surgical planning and regenerative medicine
Holographic bioprinting for vasculature; claims breakthrough in capillary-scale printing
Plant-derived recombinant human collagen bioinks; eliminates animal-source concerns
Organovo partnered with L'Oreal to develop bioprinted skin tissue that eliminates animal testing for cosmetics. The 3D-printed skin replicates human skin architecture with multiple cell layers, providing more accurate toxicity and efficacy predictions than traditional models. This collaboration demonstrates how bioprinting can transform product safety testing across industries.
In a landmark achievement, Wake Forest researchers led by Dr. Anthony Atala successfully implanted bioprinted bladders in pediatric patients with spina bifida over a decade ago. Using patients' own cells seeded onto biodegradable scaffolds, the team demonstrated that bioprinted organs could function long-term in human bodies, paving the way for more complex organ engineering.
In 2022, 3DBio Therapeutics achieved a historic first by implanting a 3D-bioprinted ear made from the patient's own cells. The 20-year-old woman born with microtia received a new outer ear created using her own cartilage cells printed into an ear-shaped collagen scaffold. This represents the first clinical implant of a bioprinted living tissue structure for permanent reconstruction.
Bioprinted products face complex regulatory requirements depending on their classification and intended use:
The FDA is actively developing bioprinting-specific guidance, recognizing the unique challenges of regulating living, manufactured tissues. Several bioprinted products have received breakthrough therapy designation to accelerate development.
Bioprinted tissues for pharmaceutical research, disease modeling, and cosmetics testing are commercially available and widely used.
FDA approval expected for skin grafts, cartilage implants (ear, nose, joints), and corneal tissues for clinical transplantation.
Vascularized tissue patches for heart repair, partial liver tissue, and kidney filtering units enter advanced clinical trials.
Bladders, blood vessels, tracheas, and other simpler organs with successful long-term implantation; islet replacement for diabetes.
First bioprinted kidneys, livers, and hearts for human transplantation - contingent on solving vascularization and scale-up challenges.
3D bioprinting is an additive manufacturing technology that uses living cells, biomaterials, and growth factors to fabricate three-dimensional tissue constructs layer by layer. Unlike traditional 3D printing, bioprinting creates structures containing viable cells that can mature into functional tissues for drug testing, disease modeling, or eventual transplantation.
The four main bioprinting technologies are: 1) Extrusion-based bioprinting - uses pneumatic or mechanical pressure to deposit bioink through a nozzle, 2) Inkjet bioprinting - deposits small droplets using thermal or piezoelectric actuators, 3) Laser-assisted bioprinting - uses laser pulses to transfer cells from a donor ribbon, and 4) Stereolithography - uses UV light to crosslink photosensitive bioinks layer by layer.
Bioinks typically contain living cells suspended in a biocompatible hydrogel matrix. Common materials include alginate, gelatin methacryloyl (GelMA), collagen, fibrin, hyaluronic acid, and decellularized extracellular matrix (dECM). These materials provide structural support while maintaining cell viability and enabling tissue maturation.
Vascularization is critical because cells cannot survive more than 100-200 micrometers from a blood supply. Without functional blood vessels, printed tissues larger than a few millimeters cannot receive oxygen and nutrients, causing cell death at the core. Creating complex, branching vascular networks that integrate with the host circulatory system remains bioprinting's greatest technical hurdle.
Simple tissues like skin grafts and cartilage are already in clinical use. More complex structures like bladders have been implanted in limited trials. Full solid organs like kidneys, livers, and hearts are projected to be 10-20 years away, with experts estimating the first bioprinted organ transplants may occur between 2035-2040, pending solutions to vascularization and immune challenges.
Key companies include Organovo (liver tissue for drug testing), CELLINK/Bico Group (bioprinters and bioinks), Aspect Biosystems (microfluidic bioprinting), 3D Systems (healthcare 3D printing), Prellis Biologics (vascularization technology), and CollPlant (plant-based collagen bioinks). Academic leaders include Wake Forest Institute for Regenerative Medicine and ETH Zurich.
Bioprinted products are regulated based on their intended use. The FDA classifies them under biologics (CBER), devices (CDRH), or combination products. Simple tissues may follow the 510(k) pathway, while complex organs require Biologics License Applications (BLA). The FDA has issued guidance documents for additive manufacturing and is developing frameworks specifically for bioprinted products.
Experience interactive bioprinting technology in our virtual lab
Bioprinting Lab Tissue Builder All Technologies All Simulations